Skip to main content
. 2021 May 25;22(11):5623. doi: 10.3390/ijms22115623

Figure 5.

Figure 5

Effects of acute exposure to Akt inhibitor, 10-[4′-(N,N-diethylamino)butyl]-2-chlorophenoxazine hydrochloride (DEBC: 10 μM) for 120 min on enhanced l-glutamate release through activated hemichannel induced by combination of subchronic administration of therapeutic-relevant concentration of VPA (500 μM) with acute (A) and subchronic (B) administration of CLZ (30 μM), QTP (10 μM) and BPZ (3 μM). Ordinate: mean ± SD (n = 6) of FCHK-evoked astroglial l-glutamate release (μM). Light and dark color columns indicate the incubation without (non) and with DEBC (10 μM), respectively. ** p < 0.01: relative to non, @ p < 0.05, @@ p < 0.01 relative to control by MANOVA with Tukey’s post-hoc test.